Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.

Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.

Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.

Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.

Abstract: A switch that can report unavailability in a label-switched network is provided. During operation, the switch can determine that a label-switched path is unavailable for forwarding a packet. The switch can then generate a notification message for collecting unavailability information at a respective upstream hop of the label-switched path. The notification message includes a depth indicator indicating the depth of collected unavailability information and an ingress label of the packet at the switch. If the switch is an intermediate switch on the label-switched path, the switch can forward the notification message to an upstream switch on the label-switched path, thereby allowing the upstream switch to collect further unavailability information in the notification message.

Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.

Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.

Abstract: A system related to black hole filtering is provided. The system can allow a dynamic routing protocol on a network device to determine whether a route learned by the dynamic routing protocol is a black hole route. The route may be learned through another source. In response to a determination that the route is the black hole route, the dynamic routing protocol may generate a routing update that indicates the route as the black hole route. The dynamic routing protocol may then advertise the routing update to each neighbor network device.

Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).

Abstract: Examples include determining a first hop for a preferred route from a networking device to a destination device, calculating a cumulative cost for the preferred route based on a cost of the first hop and an original cost of the preferred route, determining whether a secondary route is available, and, in response to a determination that the secondary route is available, determining a first hop in the secondary route. Examples also include determining a cost of the first hop in the secondary route, determining a new route from the networking device to the destination computing device based on the cumulative cost of the preferred route and the cost of the first hop in the secondary route, and entering the new route into a forwarding data structure of the networking device.

Abstract: A switch that can report unavailability in a label-switched network is provided. During operation, the switch can determine that a label-switched path is unavailable for forwarding a packet. The switch can then generate a notification message for collecting unavailability information at a respective upstream hop of the label-switched path. The notification message includes a depth indicator indicating the depth of collected unavailability information and an ingress label of the packet at the switch. If the switch is an intermediate switch on the label-switched path, the switch can forward the notification message to an upstream switch on the label-switched path, thereby allowing the upstream switch to collect further unavailability information in the notification message.

Abstract: A treatment for symptoms of migraine and cluster headaches includes operations of providing a solution of a serotonin receptor agonist (SRA) in an active mesh nebulizer, triggering the formation of a plume of particles from the active mesh nebulizer, and delivery of the plume of particles into the lungs of a patient during an inhalation process.

Abstract: Examples disclosed herein relate to a method comprising receiving, at a first label manager of a first network device, a first request to allocate a first label for a first route prefix for a first protocol, wherein the first network device and a second network device are part of a virtualized network device. The method includes receiving, at a second label manager of the second network device, a second request to determine the first label for the first route prefix for the first protocol, wherein the second request originates from the first label manager and determining, at the second label manager, the first label for the first route prefix for the first protocol. The method includes transmitting, the first label to the first label manager and transmitting, by the first label manager, the first label to a label management protocol corresponding to the first protocol, in response to the first request.

Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).

Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.

Abstract: A system and a method for eliminating data loss in a virtually aggregated network are described. A first network device may identify inactivity of a central network device present in a communication network. The central network device is responsible for distributing routing information between a plurality of network devices including the first network device. The first network device delays network route calculations until a second network device is elected from the plurality of network devices to perform functions of the central network device. The second network device generates link state information related to the plurality of network devices, and shares the link state information with the plurality of network devices. Upon receiving the link state information, the plurality of network device may resume the route calculations.

Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.

Abstract: A method of delivering a medication or a pharmaceutical product to a patient includes operations of activating an active mesh of an active mesh nebulizer, the active mesh being in contact with a liquid formulation of the medication, and configured to generate a plume of particles having a particle diameter between 1 and 6 micrometers, directing the plume of particles to a mouth of a patient during an inhalation by a patient; and stopping the plume of particles during the inhalation by the patient such that a substantial majority, or nearly all, of the plume of particles is inhaled by the patient.

Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.

Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.